MX2015016062A - Sub-poblacion de monocitos humanos para el tratamiento de enfermedades y trastornos del ojo. - Google Patents
Sub-poblacion de monocitos humanos para el tratamiento de enfermedades y trastornos del ojo.Info
- Publication number
- MX2015016062A MX2015016062A MX2015016062A MX2015016062A MX2015016062A MX 2015016062 A MX2015016062 A MX 2015016062A MX 2015016062 A MX2015016062 A MX 2015016062A MX 2015016062 A MX2015016062 A MX 2015016062A MX 2015016062 A MX2015016062 A MX 2015016062A
- Authority
- MX
- Mexico
- Prior art keywords
- population
- treatment
- cells
- disorders
- sub
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 210000001616 monocyte Anatomy 0.000 title abstract 3
- 208000035475 disorder Diseases 0.000 title abstract 2
- 208000030533 eye disease Diseases 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 4
- 210000001328 optic nerve Anatomy 0.000 abstract 2
- 210000001525 retina Anatomy 0.000 abstract 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 abstract 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 abstract 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 abstract 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 abstract 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 abstract 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/17—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361826159P | 2013-05-22 | 2013-05-22 | |
| US201361915069P | 2013-12-12 | 2013-12-12 | |
| PCT/IL2014/050463 WO2014188436A1 (en) | 2013-05-22 | 2014-05-22 | Human monocyte sub-population for treatment of eye diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015016062A true MX2015016062A (es) | 2016-08-03 |
Family
ID=51933057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015016062A MX2015016062A (es) | 2013-05-22 | 2014-05-22 | Sub-poblacion de monocitos humanos para el tratamiento de enfermedades y trastornos del ojo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10188679B2 (https=) |
| EP (1) | EP2999479B1 (https=) |
| JP (1) | JP6474082B2 (https=) |
| KR (1) | KR102257163B1 (https=) |
| CN (1) | CN105377273A (https=) |
| AU (1) | AU2014269935B2 (https=) |
| BR (1) | BR112015029299A2 (https=) |
| CA (1) | CA2913274C (https=) |
| IL (1) | IL242694B (https=) |
| MX (1) | MX2015016062A (https=) |
| WO (1) | WO2014188436A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2790712B1 (en) * | 2011-12-14 | 2016-08-31 | Yeda Research and Development Co. Ltd. | Human monocyte sub-population for treatment of central nervous system injury |
| KR20260003355A (ko) | 2015-09-08 | 2026-01-06 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 줄기 세포에서 유래된 망막색소상피의 macs 기반 정제 |
| DE102017125335B4 (de) * | 2017-10-27 | 2019-10-17 | Epiontis Gmbh | Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten |
| KR102228401B1 (ko) * | 2018-07-05 | 2021-03-16 | 고려대학교 산학협력단 | 유리체 절제술 및 안구 내 mnu 주입과 제거를 이용한 망막 변성 동물 모델의 제조방법 및 이를 이용한 망막 변성 동물 모델 |
| BR112022011339A2 (pt) * | 2019-12-11 | 2022-10-04 | Myeloid Therapeutics Inc | Composições de células terapêuticas e métodos para fabricação e usos das mesmas |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267955B1 (en) | 1995-09-15 | 2001-07-31 | Yeda Research And Development Co. Ltd. | Mononuclear phagocytes and their use to promote axonal regeneration |
| US5800812A (en) | 1995-09-15 | 1998-09-01 | Yeda Research And Development Co. Ltd. | Methods of use of mononuclear phagocytes to promote axonal regeneration |
| AU2002353465B2 (en) | 2001-11-21 | 2008-10-16 | Yeda Research And Development Co. Ltd. | Process for the manufacture of human mononuclear phagocytic leukocytes |
| CA2598029A1 (en) * | 2005-02-24 | 2006-10-05 | The Scripps Research Institute | Isolated myeloid-like bone marrow cell populations and methods of treatment therewith |
| CA2752679A1 (en) | 2009-02-20 | 2010-08-26 | The Scripps Research Institute | Isolated monocyte populations and related therapeutic applications |
| EP2790712B1 (en) | 2011-12-14 | 2016-08-31 | Yeda Research and Development Co. Ltd. | Human monocyte sub-population for treatment of central nervous system injury |
-
2014
- 2014-05-22 CN CN201480039692.9A patent/CN105377273A/zh active Pending
- 2014-05-22 BR BR112015029299A patent/BR112015029299A2/pt not_active Application Discontinuation
- 2014-05-22 WO PCT/IL2014/050463 patent/WO2014188436A1/en not_active Ceased
- 2014-05-22 CA CA2913274A patent/CA2913274C/en active Active
- 2014-05-22 MX MX2015016062A patent/MX2015016062A/es unknown
- 2014-05-22 JP JP2016514532A patent/JP6474082B2/ja not_active Expired - Fee Related
- 2014-05-22 US US14/898,732 patent/US10188679B2/en active Active
- 2014-05-22 AU AU2014269935A patent/AU2014269935B2/en not_active Ceased
- 2014-05-22 EP EP14801769.2A patent/EP2999479B1/en active Active
- 2014-05-22 KR KR1020157036168A patent/KR102257163B1/ko not_active Expired - Fee Related
-
2015
- 2015-11-19 IL IL242694A patent/IL242694B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US10188679B2 (en) | 2019-01-29 |
| EP2999479A4 (en) | 2017-02-22 |
| BR112015029299A2 (pt) | 2017-07-25 |
| WO2014188436A1 (en) | 2014-11-27 |
| CN105377273A (zh) | 2016-03-02 |
| CA2913274C (en) | 2021-10-12 |
| KR20160016874A (ko) | 2016-02-15 |
| JP6474082B2 (ja) | 2019-02-27 |
| EP2999479B1 (en) | 2021-01-06 |
| AU2014269935A1 (en) | 2016-01-21 |
| US20160166612A1 (en) | 2016-06-16 |
| AU2014269935B2 (en) | 2019-01-24 |
| EP2999479A1 (en) | 2016-03-30 |
| JP2016522830A (ja) | 2016-08-04 |
| CA2913274A1 (en) | 2014-11-27 |
| KR102257163B1 (ko) | 2021-05-27 |
| IL242694B (en) | 2021-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123459T1 (el) | Χρηση των κανναβινοειδων στη θεραπεια του συμπλεγματος οζωδους σκληρυνσης | |
| MX2021014709A (es) | Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes. | |
| MX394103B (es) | Anticuerpos anti-angptl8 y usos de estos. | |
| AR091305A1 (es) | ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO | |
| IL291784B1 (en) | Reducing systemic regulatory t cell levels or activity fortreatment of " disease and injury of the cns | |
| EA201790377A1 (ru) | Антитела к глюкагону и их применения | |
| MX366317B (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
| BR112016010166A2 (pt) | métodos para usar interleucina-10 para tratar doenças e distúrbios | |
| MX2017009694A (es) | Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l). | |
| BR112018074454A2 (pt) | composições e métodos de uso de nintedanib para tratar doenças oculares com neovascularização anormal | |
| EP4104867A3 (en) | Compositions and methods for treatment of central nervous system diseases | |
| DOP2014000174A (es) | Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas | |
| EA202090031A3 (ru) | Человеческие антитела против gfr3 и способы их применения | |
| EA201591754A1 (ru) | Человеческие антитела к na1.7 | |
| MX2015016062A (es) | Sub-poblacion de monocitos humanos para el tratamiento de enfermedades y trastornos del ojo. | |
| BR112015018438A2 (pt) | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento | |
| MX382466B (es) | Partículas inmunomodificadoras para el tratamiento de la inflamación. | |
| MX2015003140A (es) | Formulaciones de enzalutamida. | |
| AR091237A1 (es) | Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf) | |
| MX379318B (es) | Metodos para tratar trastornos de sueño de ritmo circadiano. | |
| MX2019009783A (es) | Metodo para fabricar una barra que comprende antitranspirante. | |
| AR085297A1 (es) | METODOS PARA MEJORAR EL DESARROLLO DEL CEREBRO Y LA FUNCION COGNITIVA EN LOS QUE SE EMPLEA b-HIDROXI-b-METILBUTIRATO | |
| AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
| UY37534A (es) | Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda | |
| EA201492102A1 (ru) | Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны |